Court agrees with AbbVie’s methodology for damages in Takeda case
The Delaware Court of Chancery on Tuesday ruled in favor of AbbVie, likely setting up the drugmaker to receive most of the damages it was seeking from Takeda.
AbbVie had sued Takeda in 2020, alleging a breach of contract to supply the prostate cancer drug Lupron. A year later, the Court of Chancery found that Takeda breached its supply agreement with AbbVie.
Vice Chancellor Sam Glasscock III said he found that “AbbVie’s damages methodology is reliable and appropriate,” according to the decision. He also said it was “indisputable that AbbVie suffered lasting damages as a result of the Lupron shortage.” AbbVie was seeking an estimated $480.6 million in damages from the Japanese pharma, according to Bloomberg Law.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.